MX2012002479A - Nuevos derivados de bencimidazol y su uso como agonistas del receptor x farnesoide. - Google Patents

Nuevos derivados de bencimidazol y su uso como agonistas del receptor x farnesoide.

Info

Publication number
MX2012002479A
MX2012002479A MX2012002479A MX2012002479A MX2012002479A MX 2012002479 A MX2012002479 A MX 2012002479A MX 2012002479 A MX2012002479 A MX 2012002479A MX 2012002479 A MX2012002479 A MX 2012002479A MX 2012002479 A MX2012002479 A MX 2012002479A
Authority
MX
Mexico
Prior art keywords
sup
benzimidazole derivatives
fxr agonists
new benzimidazole
new
Prior art date
Application number
MX2012002479A
Other languages
English (en)
Inventor
Bernd Kuhn
Sven Taylor
Hans Richter
Jean-Marc Plancher
Uwe Grether
Konrad Bleicher
Markus Rudolph
Rainer E Martin
Gregory Martin Benson
Song Feng
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012002479A publication Critical patent/MX2012002479A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a los compuestos de la fórmula (I) así como a las sales de los mismos farmacéuticamente aceptables que pueden ser utilizados en la forma de composiciones farmacéuticas, en donde A, B, R1, R2, R3, R4, R5, n, m y p tienen el significado dado en la reivindicación 1.
MX2012002479A 2009-09-29 2010-09-27 Nuevos derivados de bencimidazol y su uso como agonistas del receptor x farnesoide. MX2012002479A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09171700 2009-09-29
PCT/EP2010/064217 WO2011039130A1 (en) 2009-09-29 2010-09-27 New benzimidazole derivatives and their use as fxr agonists

Publications (1)

Publication Number Publication Date
MX2012002479A true MX2012002479A (es) 2012-03-26

Family

ID=43033176

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002479A MX2012002479A (es) 2009-09-29 2010-09-27 Nuevos derivados de bencimidazol y su uso como agonistas del receptor x farnesoide.

Country Status (13)

Country Link
US (1) US8309581B2 (es)
EP (1) EP2483247A1 (es)
JP (1) JP5503007B2 (es)
KR (1) KR101477872B1 (es)
CN (1) CN102574812B (es)
AU (1) AU2010303146A1 (es)
BR (1) BR112012006986A2 (es)
CA (1) CA2772815A1 (es)
HK (1) HK1171746A1 (es)
IL (1) IL218037A0 (es)
IN (1) IN2012DN01234A (es)
MX (1) MX2012002479A (es)
WO (1) WO2011039130A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031003B1 (ru) 2013-09-11 2018-10-31 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций
CN108072684B (zh) * 2016-11-11 2020-06-16 中国科学院广州生物医药与健康研究院 法尼醇x受体的新配体及其筛选方法和应用
JP2020508316A (ja) 2017-02-21 2020-03-19 ジェンフィＧｅｎｆｉｔ Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
WO2018178260A1 (en) 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
CN101479249B (zh) 2006-06-29 2012-10-10 霍夫曼-拉罗奇有限公司 苯并咪唑衍生物、其制备方法、它们作为fxr激动剂的用途及含有它们的药物制剂
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
BRPI0815696A2 (pt) * 2007-08-27 2016-06-21 Hoffmann La Roche composto derivados de benzimidazol, processo para a sua manufatura, composições farmacêuticas que os compreendem, metódo para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de fxr e uso destes compostos.
JP5222953B2 (ja) * 2007-11-15 2013-06-26 エフ．ホフマン−ラ ロシュ アーゲー ベンゾイミダゾール誘導体及びｆｘｒアゴニストとしてのその使用
CA2734034A1 (en) * 2008-09-11 2010-03-18 F. Hoffmann-La Roche Ag New benzimidazole derivatives
ES2444791T3 (es) * 2008-10-15 2014-02-26 F. Hoffmann-La Roche Ag Nuevos derivados de benzimidazol

Also Published As

Publication number Publication date
AU2010303146A1 (en) 2012-04-19
HK1171746A1 (zh) 2013-04-05
CN102574812B (zh) 2016-03-30
IN2012DN01234A (es) 2015-05-15
IL218037A0 (en) 2012-04-30
EP2483247A1 (en) 2012-08-08
JP2013505977A (ja) 2013-02-21
WO2011039130A1 (en) 2011-04-07
KR20120063536A (ko) 2012-06-15
US20110077273A1 (en) 2011-03-31
CN102574812A (zh) 2012-07-11
JP5503007B2 (ja) 2014-05-28
US8309581B2 (en) 2012-11-13
CA2772815A1 (en) 2011-04-07
BR112012006986A2 (pt) 2016-04-12
KR101477872B1 (ko) 2014-12-30

Similar Documents

Publication Publication Date Title
IN2012DN03337A (es)
MX2010005824A (es) Derivados de aminotiazol.
MX2009003939A (es) Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes.
MY138941A (en) Aryl-pyridine derivatives
MX2010002341A (es) Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.
UA108640C2 (uk) Похідні n-(імідазопіримідин-7-іл)гетероариламідів та їх застосування як інгібіторів pde10a
MX2011012017A (es) Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl).
ATE483707T1 (de) 2-cyclopropylthiazolderivate
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
MX2009013078A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotropicos de glutamato - 842.
MX2012000414A (es) Derivados piridin-4-ilo.
MX354102B (es) Derivados de bencimidazol-prolina.
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
MY156552A (en) Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
MX336071B (es) Formulaciones intravenosas de antagonistas de neurocinina 1.
MX2010003224A (es) Derivados de biaril sulfonamida.
IN2012DN01232A (es)
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
UA109037C2 (uk) Триазолопіридини
MX2011012639A (es) Sales de derivados de pirazolon azo sustituidos con biciclo, metodo de preparacion y uso de los mismos.
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
MX2008016426A (es) Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1).
MX2014003025A (es) Compuestos de triazolopiridina como inhibidores de fosfodiesterasa 10a.
MX2010005714A (es) Compuestos de piridina.

Legal Events

Date Code Title Description
FG Grant or registration